Graham Capital Management’s PAVmed PAVM Stock Holding History

Graham Capital Management’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-92	Closed	-$102K	–	995
2021 Q4	$102K	Buy	+92	New	+$200K	﹤0.01%	504

Other funds holding PAVM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Graham Capital Management's PAVM Position: Q1 2022 in Review

Graham Capital Management sold out of PAVmed (PAVM) in Q1 2022, closing a stake of 92 shares — an estimated $102K sold.

Graham Capital Management first reported a position in PAVM in Q4 2021 and held it in 1 quarter. The position peaked at $102K in Q4 2021. 94 funds tracked by Wall St. Rank hold PAVM as of Q1 2022.

Graham Capital Management reported no remaining PAVmed position as of Q1 2022 after selling out during the quarter.
Graham Capital Management sold 92 PAVmed shares in Q1 2022, an estimated $102K.
Graham Capital Management first reported a position in PAVmed in Q4 2021 and held it in 1 quarter.
Graham Capital Management's PAVmed position peaked at $102K in Q4 2021.
94 funds tracked by Wall St. Rank held PAVmed as of Q1 2022.

Based on Graham Capital Management's 13F filing for Q1 2022, filed 16 May 2022.